Testing a new immunotherapy for advanced solid tumors
Part of Cancer clinical trials.
This trial tests a new immunotherapy drug, GIGA-564, for people with advanced solid tumors that have not responded to or have returned after standard treatments. The goal is to see if the drug is safe and effective, and to find the best dose.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You have advanced cancer that has spread (metastatic) and has not responded to standard treatments or has come back after at least one treatment.
- You have at least one tumor that can be measured on a scan (like a CT or MRI).
- You are feeling well enough to do most of your daily activities (ECOG 0 or 1).
- Your blood counts and organ function (kidney, liver, heart) are within range as tested by your doctor.
- You have not had prior treatment with certain immune therapies (like ipilimumab, or drugs targeting CCR8, CD25, or TIGIT).
- You do not have an active autoimmune disease that required treatment in the last 2 years, or active untreated brain metastases.
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This trial tests a new drug, GSK5533524, alone or with other treatments, for people with advanced solid tumors that have stopped responding to standard therapies. It aims to find out if the drug is safe and shows early signs of working.
This Phase 1 trial tests a new antibody drug (GNC-039) that targets a specific feature found on some cancer cells. It is for adults with solid tumors that have come back or stopped responding to standard treatment, aiming to see safety and early signs of effectiveness.
This Phase 1/2 trial tests an immune-based treatment for advanced (Stage III–IV) GI cancer. You may be able to join only if your tumor shows certain “marker” proteins on special lab staining, and your blood and organ tests meet study limits.
This trial tests an injection of your own immune cells (tumor-infiltrating lymphocytes) to see if they can fight advanced solid tumors like stomach or lung cancer. Doctors will remove one of your tumors, grow the immune cells from it, and then give them back to you.
This study tests a new drug (BGB-26808) alone or with another drug (tislelizumab) for people with advanced solid tumors that haven't responded to standard treatments. The goal is to see if the combination can help shrink tumors or slow their growth.
This Phase 1 trial tests a new drug called IUAb190708 designed to help your immune system fight advanced or recurrent solid cancers. The study will evaluate its safety, how your body handles it, and whether it works against your tumor.
Hear when a new Advanced or Metastatic Solid Tumor Malignancies trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.